NCT01870037 - Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

February 17, 2018

Conditions

Overactive Bladder

Interventions

DRUG

Placebo (PBS-20% sucrose)

DRUG

hMaxi-K

Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)

Trial Locations (3)

NYU, New York

AccuMed Research Associates, Garden City

Premier Medical Group of the Hudson Valley, PC, Poughkeepsie